Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | ATP4A | P20648 | 1/20 | 0.48 |
| ▸ | ATP4B | P51164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892621 | 0.85 | NPC1 (0.58) | MAPTSMN1; SMN2HTTKDM4EALDH1A1 | |
| SCHEMBL2905332 | 0.85 | RAB9A (0.52) | SMN1; SMN2KDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL15058530 | 0.85 | MEN1 (0.58) | L3MBTL1MAPTTDP1MAPK1TSHR | |
| SCHEMBL8283853 | 0.84 | TSHR (0.50) | L3MBTL1MAPTTDP1MAPK1GRM5 | |
| SCHEMBL12226851 | 0.84 | L3MBTL1 (0.49) | L3MBTL1MAPTTDP1MAPK1GRM5 | |
| SCHEMBL4502335 | 0.84 | MAPT (0.49) | L3MBTL1MAPTTDP1MAPK1GRM5 | |
| SCHEMBL4120541 | 0.83 | TSHR (0.49) | L3MBTL1MAPTTDP1MAPK1GRM5 | |
| SCHEMBL17544850 | 0.83 | ATP4A (0.47) | L3MBTL1MAPTTDP1MAPK1ATP4A | |
| SCHEMBL2904391 | 0.83 | ATP4A (0.43) | L3MBTL1MAPTTDP1MAPK1ATP4A | |
| SCHEMBL24992521 | 0.81 | USP28 (0.43) | L3MBTL1MAPTTDP1MAPK1ATP4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| US-9493438-B2 | 4,4-difluoro-piperidine-compounds | ROTTAPHARM S.R.L. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-9493438-B2 | 4,4-difluoro-piperidine-compounds | ROTTAPHARM S.R.L. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-9493438-B2 | 4,4-difluoro-piperidine-compounds | ROTTAPHARM S.R.L. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-2820007-B1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | Rottapharm Biotech Srl (IT) | 2016-04-20 | — | — | EP | disclosed |
| EP-2820007-B1 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS | Rottapharm Biotech Srl (IT) | 2016-04-20 | — | — | EP | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-20070015747-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA, N.V. | 2007-01-18 | — | — | US | disclosed |
| CN-1894236-A | Amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARM LTD (IE) | 2007-01-10 | — | — | CN | disclosed |
| EP-1217001-B1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | EISAI CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6747028-B1 | 1,2-SUBSTITUTED BENZIMIDAZOLES HAVING ANTIVIRAL ACTIVITY | HANSSEN PHARMACEUTICA, N.V. (BE) | 2004-06-08 | — | — | US | disclosed |
| EP-1196409-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-04 | — | — | EP | disclosed |
| US-6599917-B1 | A squalene-synthesizing enzyme inhibitor, a cholesterol biosynthesis inhibitor and a triglyceride biosynthesis inhibitor | EISAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| CN-1377349-A | Quinuclidine compound and medicine containing the same as active ingredient | EISAI CO LTD (JP) | 2002-10-30 | — | — | CN | disclosed |
| EP-1217001-A1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
| EP-1196409-A2 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000612-A2 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015747-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | SARS1, ACE, MAVS | L3MBTL1 3155/4885MAPT 4749/4885TDP1 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.